NextCure (NXTC) Cash & Equivalents (2018 - 2026)

NextCure's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $15.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 30.51% year-over-year to $15.2 million; the TTM figure through Mar 2026 stood at $15.2 million (down 30.51% YoY), while the FY2025 annual figure was $26.0 million, down 6.29% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $15.2 million, down from $26.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $31.0 million in Q3 2022, with the low at $4.9 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $21.8 million (2025), against an average of $20.6 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 181.38% in 2023, then sank 76.53% in 2025.
• NextCure's Cash & Equivalents stood at $26.6 million in 2022, then sank by 50.87% to $13.1 million in 2023, then soared by 111.95% to $27.7 million in 2024, then declined by 6.29% to $26.0 million in 2025, then sank by 41.62% to $15.2 million in 2026.
• Business Quant data shows NXTC's Cash & Equivalents at $15.2 million in Q1 2026, $26.0 million in Q4 2025, and $7.3 million in Q3 2025.